Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
07:09pm, Monday, 02'nd Oct 2023
Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients' T cells, which fight hostile c
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
01:54pm, Thursday, 21'st Sep 2023
AbbVie is entering a new era but is well prepared to return to its winning ways. Gilead Sciences offers investors steady and reliable performance and a great dividend.
Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
09:01am, Wednesday, 20'th Sep 2023
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Time for Gilead Sciences-Heavy ETFs?
03:05pm, Tuesday, 12'th Sep 2023
Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
12:46pm, Monday, 11'th Sep 2023
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.
3 Dividend Stocks for September 2023
12:00pm, Saturday, 09'th Sep 2023
#Morningstar #PfizerStock #DividendStocks Dividend investors: Put these cheap stocks on your buy list. 00:00 Introduction 00:28 Pfizer PFE 01:03 Medtronic MDT 01:34 Gilead Sciences GILD Susan Dziub
Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans
03:17am, Saturday, 09'th Sep 2023
Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained stable
Bank of America says buy Gilead
02:31pm, Friday, 08'th Sep 2023
The "Halftime Report" traders debate the biggest analyst calls of the day.
Gilead Stock Looks Underappreciated and Oversold, Say BofA Analysts
11:20am, Friday, 08'th Sep 2023
BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.
Gilead Sciences, Inc. (GILD) Wells Fargo Healthcare Conference - (Transcript)
03:21pm, Wednesday, 06'th Sep 2023
Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo Healthcare Conference September 6, 2023 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit
Call of the day: The health care trade
01:30pm, Wednesday, 06'th Sep 2023
CNBC's Halftime traders Steve Weiss, Liz Young, Joe Terranova, and Brian Belski discuss the call of the day: health care.
Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
02:40pm, Tuesday, 29'th Aug 2023
Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and a l
Nearing Retirement? These Stocks Will Pay You For Life
09:45am, Tuesday, 29'th Aug 2023
Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
01:32pm, Friday, 25'th Aug 2023
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
GILD Stock Alert: FDA Approves Gilead Sciences' Veklury Covid-19 Treatment
11:39am, Thursday, 24'th Aug 2023
Gilead Sciences (NASDAQ: GILD ) stock is on the move Thursday following FDA approval for its Veklury Covid-19 treatment. This saw the FDA approve the company's supplemental new drug application (sNDA)
